Teclistamab

0:22:21

TECVAYLI (Teclistamab) Everything You Need to Know

0:02:20

How frequently should TECVAYLI (teclistamab) be given to myeloma patients?

0:02:33

Teclistamab Approval For Multiple Myeloma Treatment | Ross Firestone, MD, PhD | ASCO 2023

0:01:46

How Teclistamab Treatment Affects Quality of Life | Rakesh Popat, MD | EHA 2022

0:01:14

Clinical benefit of teclistamab vs real-world physician’s choice for R/R multiple myeloma

0:06:39

Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023

0:01:39

Real-world efficacy & safety of teclistamab in patients with BCMA-pretreated R/R multiple myeloma

0:00:46

2-year follow-up of MajesTEC-1: teclistamab in R/R multiple myeloma

0:04:59

REAL-WORLD SCHEDULE DE-ESCALATION OF TECLISTAMAB IN PATIENTS WITH RRMM | Carlyn Tan, MD | EHA 2024

0:06:38

Real-world efficacy & safety of teclistamab in patients with heavily pretreated R/R multiple myeloma

0:14:31

Teclistamab - Guest Lecture

0:01:53

MajesTEC‐1 update: rates of infection in patients with myeloma receiving teclistamab

0:04:30

MajesTEC-1: Longer Follow-up Teclistamab + Tocilizumab Prophylaxis for CRS in RR multiple myeloma

0:02:52

Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple ...

0:58:00

Know Your Myeloma Immunotherapy: Teclistamab and other Bispecifics

0:01:50

Real-world outcomes of teclistamab treatment in R/R multiple myeloma

0:01:27

Comparative efficacy of teclistamab vs pom+dex in triple-class exposed R/R myeloma

0:01:45

The value of teclistamab in R/R myeloma & strategies to mitigate toxicities

0:06:59

Teclistamab in Combination with Sub-Q Daratumumab and Lenalidomide in Myeloma Pts: MajesTEC-2

0:02:04

Approval of teclistamab in triple-class refractory multiple myeloma

0:01:42

Key considerations for clinicians when treating multiple myeloma with teclistamab

0:01:12

Insights into MajesTEC-4: assessing the role of teclistamab as maintenance in patients with myeloma

0:55:48

Hitting the BCMA Target in Multiple Myeloma

0:01:59

A subgroup analysis of MajesTEC-1: teclistamab in multiple myeloma with high-risk features